The rumors of Pfizer Inc.’s interest in a mega-purchase of Seagen Inc. became true on 13 March when the companies announced that the big pharma would pay $43bn in cash for the antibody-drug conjugate (ADC) pioneer. Confirming the deal gave Pfizer an opportunity to outline its big oncology ambitions not only for the Seagen assets but for the combined company going forward.
Pfizer Pays $43bn For Seagen With Goal Of Rapidly, Globally Advancing ADCs
Speedy COVID-19 Strategies Will Be Applied In Cancer R&D
Pfizer expects its acquisition of Seagen to result in $10bn in new revenue by 2030 as the big pharma applies its resources to the target company’s pioneering antibody-drug conjugate technology.
More from Deals
• By
Plus deals involving GV20/Mitsubishi Tanabe, Kaken/Alumis, AstraZeneca/Alteogen and deal terminations involving Clover/Gavi Alliance and Rhythm/RareStone.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
Plus deals involving Relmada/Trigone, Alvotech/Xbrane, OPKO Health/Entera, iOncologi/TargImmune and more.
• By
Merck & Co., which already has an oral PCSK9 inhibitor in Phase III, licensed Hengrui’s Lipoprotein(a)-lowering small molecule HRS-5346 outside of Greater China for $200m up front.